Psyched: Numinus, MAPS To Spearhead MDMA Trials; Vancouver Plans To Decriminalize Drugs

Numinus Wellness (TSXV:NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada.

The pair will first seek permission to perform a single-arm, open-label, compassionate access trial, which is a special type of license granted by Health Canada when drug manufacturers anticipate exceptional demand for a drug.

Click here to read more.